Article
Curcumin lowers erlotinib resistance in non-small cell lung carcinoma cells with mutated EGF receptor.
Oncology research - 1 Jan 2013
Li Shanqun, Liu Zilong, Zhu Fen, Fan Xiaohong, Wu Xiaodan, Zhao Heng, Jiang Liyan
Abstract excerpt
Non-small cell lung cancer (NSCLC) patients with activating mutations in the epidermal growth factor receptor (EGFR) are responsive to erlotinib, an EGFR-tyrosine kinase inhibitor (EGFR-TKI). However, patients with secondary somatic EGFR mutations are resistant to EGFR-TKI treatment. In this study, we investigated the effect of curcumin on the tumor growth of erlotinib-resistant NSCLC cells. Cell proliferation...
Topics
- Animals
- Antineoplastic Combined Chemotherapy Protocols
- Apoptosis
- Carcinoma, Non-Small-Cell Lung
- Cell Line, Tumor
- Curcumin
- Down-Regulation
- Drug Resistance, Neoplasm
- Drug Synergism
- ErbB Receptors
- Erlotinib Hydrochloride
- Female
- Humans